Article, News
Topped up with cash, Prescient presses on in US$280 billion industry
COVID may have dominated headlines in 2020 causing at least 3 million deaths as reported by the World Health Organisation, but in the same year nearly…
Article, News
The cancer-fighting tech disabling ‘force fields’ around tumours
SX-listed biotech Prescient Therapeutics has unveiled the second component of its CellPryme cell therapy enhancement platform on stage at the prestigious CAR-TCR Summit in Boston….
News
3 major milestones in 8 weeks as biotech links with US giant
ASX-listed biotech Prescient Therapeutics is crossing a major inflection point on the back of three milestone announcements made within a span of less than eight…
Article, News
Prescient signs cell manufacturing deal ahead of OmniCAR trials
An Australian company developing personalised therapies for cancer has joined forces with a specialist cell therapy manufacturer to bolster its capabilities in the lead-up to…
Article, News
Prescient unveils new platform after 18 months in stealth mode
Australian biotech company Prescient Therapeutics has publicly revealed its high-performing cell therapy enhancement platform named CellPryme-M, developed in collaboration with the Peter MacCallum Cancer Centre.